LivaNova (NASDAQ:LIVN) Price Target Raised to $80.00

LivaNova (NASDAQ:LIVN) had its target price raised by Mizuho from $75.00 to $80.00 in a research report released on Thursday morning, Benzinga reports. The firm currently has a buy rating on the stock.

Other equities research analysts also recently issued reports about the stock. Needham & Company LLC reaffirmed a buy rating and issued a $72.00 price objective on shares of LivaNova in a research report on Wednesday, May 1st. StockNews.com raised shares of LivaNova from a hold rating to a buy rating in a research report on Thursday, April 25th. Robert W. Baird increased their target price on shares of LivaNova from $56.00 to $62.00 and gave the company a neutral rating in a research report on Thursday, February 22nd. Finally, Barclays increased their target price on shares of LivaNova from $57.00 to $61.00 and gave the company an equal weight rating in a research report on Monday, February 26th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and an average target price of $66.20.

LivaNova Price Performance

Shares of NASDAQ LIVN opened at $64.15 on Thursday. The firm’s 50-day moving average price is $54.71 and its 200-day moving average price is $51.06. LivaNova has a 1-year low of $42.75 and a 1-year high of $64.36. The firm has a market capitalization of $3.47 billion, a P/E ratio of -106.92 and a beta of 0.92. The company has a current ratio of 3.17, a quick ratio of 2.51 and a debt-to-equity ratio of 0.50.

LivaNova (NASDAQ:LIVN) last posted its earnings results on Wednesday, May 1st. The company reported $0.73 EPS for the quarter, topping the consensus estimate of $0.45 by $0.28. The company had revenue of $294.90 million during the quarter, compared to the consensus estimate of $278.17 million. LivaNova had a negative net margin of 2.68% and a positive return on equity of 13.59%. The firm’s revenue for the quarter was up 12.0% on a year-over-year basis. During the same period in the previous year, the firm posted $0.43 earnings per share. Equities research analysts anticipate that LivaNova will post 3.01 earnings per share for the current fiscal year.

Institutional Trading of LivaNova

Institutional investors have recently modified their holdings of the business. Norges Bank purchased a new stake in LivaNova in the 4th quarter worth approximately $26,064,000. Ameriprise Financial Inc. lifted its stake in LivaNova by 96.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 916,632 shares of the company’s stock worth $48,471,000 after purchasing an additional 449,136 shares in the last quarter. Primecap Management Co. CA lifted its stake in LivaNova by 7.3% in the 3rd quarter. Primecap Management Co. CA now owns 5,785,360 shares of the company’s stock worth $305,930,000 after purchasing an additional 395,940 shares in the last quarter. Loomis Sayles & Co. L P lifted its stake in LivaNova by 31.1% in the 3rd quarter. Loomis Sayles & Co. L P now owns 879,740 shares of the company’s stock worth $46,520,000 after purchasing an additional 208,755 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in LivaNova in the 4th quarter worth approximately $8,330,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.